Aptahem AB (publ) (APTA.ST)
SEK 1.7
(6.25%)
SEK 1.7
(6.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.99 Million SEK | -4.78% |
| 2022 | 9.44 Million SEK | 316.79% |
| 2021 | 2.26 Million SEK | -49.06% |
| 2020 | 4.45 Million SEK | 114.31% |
| 2019 | 2.07 Million SEK | -63.85% |
| 2018 | 5.74 Million SEK | 252.6% |
| 2017 | 1.62 Million SEK | 13.3% |
| 2016 | 1.43 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.67 Million SEK | 18.67% |
| 2024 Q1 | 2.25 Million SEK | -74.99% |
| 2023 Q2 | 9.99 Million SEK | 37.06% |
| 2023 Q4 | 8.99 Million SEK | 257.34% |
| 2023 Q3 | 2.51 Million SEK | -74.79% |
| 2023 FY | 8.99 Million SEK | -4.78% |
| 2023 Q1 | 7.28 Million SEK | -22.87% |
| 2022 Q2 | 2.73 Million SEK | -86.55% |
| 2022 Q4 | 9.44 Million SEK | 154.85% |
| 2022 Q3 | 3.7 Million SEK | 35.63% |
| 2022 Q1 | 20.33 Million SEK | 796.91% |
| 2021 Q2 | 2.82 Million SEK | 0.0% |
| 2021 Q4 | 2.26 Million SEK | -29.31% |
| 2021 Q3 | 3.2 Million SEK | 13.44% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | 3.571% |
| Amniotics AB (publ) | 10.54 Million SEK | 14.688% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -103.295% |
| BioArctic AB (publ) | 139.5 Million SEK | 93.55% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.425% |
| Genovis AB (publ.) | 98.04 Million SEK | 90.823% |
| LIDDS AB (publ) | 3.75 Million SEK | -139.559% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 92.742% |
| OncoZenge AB (publ) | 1.69 Million SEK | -429.595% |
| Saniona AB (publ) | 86.08 Million SEK | 89.547% |
| Simris Alg AB (publ) | 148.93 Million SEK | 93.959% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 77.978% |
| AcouSort AB (publ) | 10.37 Million SEK | 13.299% |
| Active Biotech AB (publ) | 13.4 Million SEK | 32.852% |
| Camurus AB (publ) | 414.81 Million SEK | 97.831% |
| Cantargia AB (publ) | 54.97 Million SEK | 83.631% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -134.441% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 51.347% |
| Mendus AB (publ) | 51.22 Million SEK | 82.435% |
| Kancera AB (publ) | 17.97 Million SEK | 49.951% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 22.225% |
| Lipum AB (publ) | 7.53 Million SEK | -19.366% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -74.444% |
| NextCell Pharma AB | 13.68 Million SEK | 34.27% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.134% |
| Xintela AB (publ) | 14.01 Million SEK | 35.799% |
| Ziccum AB (publ) | 6.38 Million SEK | -40.855% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 34.664% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -281.425% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 53.048% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 87.477% |
| CombiGene AB (publ) | 4.15 Million SEK | -116.502% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 87.348% |
| Intervacc AB (publ) | 21.68 Million SEK | 58.497% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 91.559% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 73.997% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 66.31% |
| Corline Biomedical AB | 6.78 Million SEK | -32.535% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 85.335% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 44.172% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 80.516% |
| Fluicell AB (publ) | 8.91 Million SEK | -0.929% |
| Biovica International AB (publ) | 34.76 Million SEK | 74.12% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 22.885% |
| Abliva AB (publ) | 16.78 Million SEK | 46.381% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 95.807% |
| 2cureX AB (publ) | 2.93 Million SEK | -206.57% |
| I-Tech AB | 16.2 Million SEK | 44.475% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.241% |
| Cyxone AB (publ) | 4.69 Million SEK | -91.688% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 32.489% |
| Biosergen AB | 5.08 Million SEK | -76.948% |
| Nanologica AB (publ) | 79.32 Million SEK | 88.657% |
| SynAct Pharma AB | 51.83 Million SEK | 82.641% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -13.194% |
| BioInvent International AB (publ) | 90.45 Million SEK | 90.052% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -73.204% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 95.045% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -401.551% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 29.396% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -23.937% |